Plasma coagulation factors, adenosine diphosphate-induced platelet aggregation, and fibrinolytic activity were studied in male survivors of myocardial infarction and in healthy normal men. Infarction survivors had significant elevations of factors VIII and X and of adenosine diphosphate-induced platelet aggregation. The fibrinolytic system was altered toward reduced plasminogen activation, increased antiurokinase activity, and elevated antiplasmin activity. These findings suggest that some men with prior myocardial infarction have a heightened tendency to thrombogenesis. This tendency may represent a response to previous cardiac insult or may contribute to its pathogenesis.
D
URING the 19th century, Karl von Rokitansky postulated that fibrin deposition on the arterial intima was the primary pathological process in atherogenesis.1 This idea has stimulated considerable 20th century interest in the relationship between blood coagulation and coronary atherosclerosis.2 For the most part, attention has been directed to the detection in vitro of the so-called hypercoagulable state, an in vivo condition wherein the postulated balance between clotpromoting and clot-reducing tendencies is shifted toward thrombogenesis.5 In some investigations, excessive amounts of thromboplastin generation, coagulation factor activity, platelet stickiness, and platelet numbers have been found.7-10 In addition, diminished blood fibrinolytic activity has been noted in certain patients.'1 However, most studies have examined just one or a few aspects of the hemostatic mechanism, and no overall picture of the coagulation status in patients with ischemic heart disease has arisen. This paper describes the results of a broad coagulation survey performed in normal persons and in patients with prior myocardial infarction. The work began as an ancillary study to the National Coronary Drug Project, a longterm study of the effects of cholesterollowering drugs on male patients with documented myocardial infarction.12 13 Results of the present interim data analysis suggest that statistically significant differences in certain coagulation factors, in platelet aggregation, and in fibrinolytic activity exist between normal men and male patients with ischemic heart disease (before treatment with cholesterol-lowering drugs). Materials The age distributions, racial characteristics, heights, weights, and serum cholesterol and triglyceride values in the study groups are compared in table 1. The CD group was significantly older, had higher triglyceride levels, and contained more black patients than the normal group (P 0.01 by the MannWhitney U-test). The two groups were similar in height, weight, and cholesterol level. Cardiac patients were taking a variety of medications at the time of coagulation testing. The drugs most frequently used included digitalis preparations, thiazide diuretics, aspirin-containing compounds, and nitroglycerin.
Variation Between Visits
After tabulating the results of 11 coagulation tests performed at each monthly visit of patients in the two study groups, we compared the mean values within each group by month, using the paired t-test. For purposes of statistical analysis, outlier pairs were excluded. In the normal group, average monthly test results differed significantly for antiplasmin activity and for ADP-induced platelet aggregation (P < 0.05). Among CD patients, monthly means differed for only factor II activity (P < 0.05).
The month-to-month relationship of test results within individual members of each group was evaluated by plotting scatter diagrams of visit 1 vs. visit 2 test values. In all cases, a roughly linear relationship was apparent, and correlation coefficients were calculated (table 2). In the normal group, seven of 11 tests showed significant positive correlations; for coronary drug patients, eight of 11 tests had significant month-to-month positive correlations. Current concepts of the hemostatic mechanism23 suggest that thrombosis occurring in response to vascular injury begins with local vessel contraction, platelet-to-vessel adhesion, and platelet-to-platelet aggregation. Subsequently, the enzymatic coagulation cascade is activated, and clotting proceeds by way of the "intrinsic" or`extrinsic pathways to the deposition of a fibrin clot at the site of injury. Figure 2 Plasma euglobulin lysis, antiurokinase, and antiplasmin activity in the two study groups. The pattern of abnormalities demonstrated in the present study suggests that a tendency to excessive thrombus formation may exist in male patients with prior myocardial infarction. By in vitro testing, platelet-to-platelet binding is greater than normal, the capacity for activation of plasminogen is reduced, and the inhibition of plasminogen activator and plasmin is increased. The platelet response to ADP in the cardiac group probably would have been even greater if nitroglycerin, rawolfia drugs, aspirin, and propranolol had not been used. [34] [35] [36] Given an appropriate vascular insult, the hemostatic mechanism in post-infarction patients might readily respond by forming a platelet plug and triggering the coagulation sequence. Enzymatic clotting reactions could proceed through elevated factor VIII and X activities and lead to thrombin generation with fibrin clot formation. In the presence of a disordered fibrinolytic mechanism, the normal system of checks and balances would be shifted toward the permanent deposition of fibrin on the arterial wall or in the arterial lumen.
These hematological data were collected primarily to provide baseline information for later use in evaluating the action of lipidlowering drugs on the hemostatic mechanism.
Thus far, the data have provided information useful in formulating a concept of the hemostatic mechanism in male survivors of myocardial infarction. The question of pathogenesis in ischemic heart disease, however, Circulation, Volume XLIII, April 1971 remains as elusive as ever. Follow-up studies of the normal and CD groups are underway. These studies should be helpful in determining the prognostic significance of coagulation testing in these patients and also in demonstrating the effects of certain lipid-lowering drugs on the coagulation mechanism.
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